• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Agilent Announces CFO Transition

    7/15/25 8:30:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $A alert in real time by email

    Agilent Technologies Inc. (NYSE:A) today announced that effective July 31, Senior Vice President and Chief Financial Officer Bob McMahon will step down from his role as he relocates to the East Coast for family reasons and prepares for the next chapter in his career.

    Following McMahon's departure, Rodney Gonsalves, Agilent's current corporate controller and principal accounting officer, will additionally serve as interim CFO until McMahon's successor is named.

    "I want to sincerely thank Bob for his seven impactful years of service at Agilent. His leadership and contributions have played an important role in our company's growth, and we wish him the best in his future endeavors," said President and CEO Padraig McDonnell. "Additionally, we are confident in Rodney's demonstrated decades-long leadership in multiple senior finance-management roles as we complete a timely and thorough global search for our next CFO with the support of a leading executive search firm."

    Agilent will release financial results for the third quarter of fiscal year 2025 after the stock market closes on Wednesday, Aug. 27, 2025. In addition, the company will host a conference call to discuss the results at 1:30 p.m. Pacific that same day. Agilent expects its financial results for the third quarter of fiscal year 2025 to be within the guidance range it previously provided. Agilent remains confident in its long-term plans.

    About Agilent Technologies

    Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom.

    Follow Agilent on LinkedIn and Facebook.

    Forward-Looking Statements

    This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding Agilent's growth prospects, business, financial results, revenue, non-GAAP earnings guidance for the third quarter and full fiscal year 2025, and the effects of its new organizational structure, operational transformation and market-focused strategy. These forward-looking statements involve risks and uncertainties that could cause Agilent's results to differ materially from management's current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of Agilent's customers' businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing; and the risk that Agilent is not able to realize the savings expected from integration and restructuring activities. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its operational transformation, market-focused strategy and cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that its cost-cutting initiatives will impair its ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on its operations, its markets and its ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the impact relating to or arising from changes to tariffs, import/export or trade policies; the ability of its supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent's filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the fiscal quarter ended April 30, 2025. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250715835438/en/

    Investor Contact:

    Parmeet Ahuja

    +1 408-345-8948

    [email protected]

    Media Contact:

    Andréa Topper

    +1 408-709-0060

    [email protected]

    Get the next $A alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $A

    DatePrice TargetRatingAnalyst
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    8/28/2024$157.00Overweight
    Wells Fargo
    7/10/2024$135.00 → $150.00Neutral → Buy
    Citigroup
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/3/2024$135.00Hold
    Jefferies
    4/5/2024$145.00 → $163.00Hold → Buy
    Stifel
    12/13/2023$140.00Outperform
    Wolfe Research
    12/12/2023$130.00 → $133.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $A
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Agilent Announces CFO Transition

      Agilent Technologies Inc. (NYSE:A) today announced that effective July 31, Senior Vice President and Chief Financial Officer Bob McMahon will step down from his role as he relocates to the East Coast for family reasons and prepares for the next chapter in his career. Following McMahon's departure, Rodney Gonsalves, Agilent's current corporate controller and principal accounting officer, will additionally serve as interim CFO until McMahon's successor is named. "I want to sincerely thank Bob for his seven impactful years of service at Agilent. His leadership and contributions have played an important role in our company's growth, and we wish him the best in his future endeavors," said Pr

      7/15/25 8:30:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent to Showcase New Products and Innovations at HPLC 2025

      Agilent Technologies Inc. (NYSE:A) today announced that they will introduce their latest Hybrid Multisampler and highlight the new LC Single Quadrupole Mass Spectrometers at the upcoming HPLC 2025 conference in Bruges, Belgium. These new additions are designed to boost laboratory efficiency and deliver superior results. Exhibition attendees will be able to see how these products can streamline operations and enhance analytical outcomes. The Agilent InfinityLab Pro iQ Series, launched at ASMS 2025, represents the next generation of LC-mass detection. With innovative hardware advancements, the series delivers enhanced sensitivity and analytical performance for oligonucleotides, therapeutic

      6/12/25 8:00:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Smackover Lithium's South West Arkansas Project Receives Royalty Rate Approval From the Arkansas Oil and Gas Commission

      LEWISVILLE, Ark., May 29, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, is pleased to announce that the Arkansas Oil and Gas Commission ("AOGC") has unanimously approved the establishment of a 2.5% royalty rate for the Reynolds Unit for Phase I of its South West Arkansas ("SWA") Project in Lafayette and Columbia Counties. This is the first royalty rate for lithium from brine extraction that has been approved by the AOGC, establishing an important precedent for lithium development companies operating in Arkansas. SWA Lithium LLC applied for a quarterly gross royalty of

      5/29/25 8:30:27 AM ET
      $A
      $SLI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Major Chemicals

    $A
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Gonsalves Rodney (Amendment)

      4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      10/20/23 1:07:25 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      9/29/23 4:03:46 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Agilent upgraded by Barclays with a new price target

      Barclays upgraded Agilent from Underweight to Equal Weight and set a new price target of $145.00 from $135.00 previously

      2/10/25 6:55:03 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wells Fargo initiated coverage on Agilent with a new price target

      Wells Fargo initiated coverage of Agilent with a rating of Overweight and set a new price target of $157.00

      8/28/24 7:20:29 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent upgraded by Citigroup with a new price target

      Citigroup upgraded Agilent from Neutral to Buy and set a new price target of $150.00 from $135.00 previously

      7/10/24 7:22:08 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    SEC Filings

    See more
    • SEC Form 8-K filed by Agilent Technologies Inc.

      8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

      7/15/25 8:43:34 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 144 filed by Agilent Technologies Inc.

      144 - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      7/1/25 12:45:28 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Agilent Technologies Inc.

      10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

      5/30/25 7:02:43 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Senior Vice President Dimarco Bret covered exercise/tax liability with 141 shares, decreasing direct ownership by 3% to 5,475 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      7/7/25 4:04:41 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President and CEO Mcdonnell Padraig sold $177,100 worth of shares (1,508 units at $117.44), decreasing direct ownership by 4% to 37,448 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      7/3/25 4:46:35 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Senior Vice President Kirkwood Jonah Prevost covered exercise/tax liability with 30 shares, decreasing direct ownership by 0.37% to 8,159 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      7/1/25 1:40:18 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

      SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/12/24 1:27:37 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Agilent Technologies Inc.

      SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/12/24 11:54:03 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Agilent Technologies Inc.

      SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/4/24 10:57:57 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $A
    Leadership Updates

    Live Leadership Updates

    See more
    • Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

      Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

      4/24/25 8:00:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent to Acquire North American CDMO BIOVECTRA

      Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati

      7/22/24 9:01:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

      Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

      6/26/24 8:00:00 AM ET
      $A
      $ANIK
      $AVNT
      $MASI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical/Dental Instruments
      Health Care

    $A
    Financials

    Live finance-specific insights

    See more
    • Agilent Announces CFO Transition

      Agilent Technologies Inc. (NYSE:A) today announced that effective July 31, Senior Vice President and Chief Financial Officer Bob McMahon will step down from his role as he relocates to the East Coast for family reasons and prepares for the next chapter in his career. Following McMahon's departure, Rodney Gonsalves, Agilent's current corporate controller and principal accounting officer, will additionally serve as interim CFO until McMahon's successor is named. "I want to sincerely thank Bob for his seven impactful years of service at Agilent. His leadership and contributions have played an important role in our company's growth, and we wish him the best in his future endeavors," said Pr

      7/15/25 8:30:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Reports Second-Quarter Fiscal Year 2025 Financial Results

      Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the second quarter of 2024. Outlook for full 2025 fiscal year and Q3 Full-year revenue outlook is now in the range of $6.73 billion to $6.81 billion, representing a range of up 3.4% to 4.6% reported, while maintaining 2.5% to 3.5% core(1). Non-GAAP E

      5/28/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Announces Cash Dividend of 24.8 Cents per Share

      Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on July 23, 2025, to all shareholders of record as of the close of business on July 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted ans

      5/21/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials